Download PDF
Thromb Haemost 2015; 113(06): 1378-1380
DOI: 10.1160/TH14-10-0892
Letters to the Editor
Schattauer GmbH

Thrombopoietin receptor agonists significantly increase the risk of portal vein thrombosis in liver diseases: Meta-analysis of RCTs

Xingshun Qi   *
1   Department of Gastroenterology, General Hospital of Shenyang Military Area, Shenyang, China
2   Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, China
,
Valerio De Stefano   *
3   Institute of Hematology, Catholic University, Rome, Italy
,
Xiaozhong Guo
1   Department of Gastroenterology, General Hospital of Shenyang Military Area, Shenyang, China
,
Daiming Fan
2   Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, China
› Author Affiliations
Further Information

Publication History

Received: 28 October 2014

Accepted after major revision: 10 January 2015

Publication Date:
18 November 2017 (online)

    Permissions and Reprints

 

* The first two authors contributed equally to this work.


 

  • References

  • 1 McHutchison JG. et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357: 2227-2236.
    CrossrefPubMedGoogle Scholar
  • 2 Afdhal NH. et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 2012; 367: 716-724.
    CrossrefPubMedGoogle Scholar
  • 3 Dultz G. et al. Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura. J Hepatol 2011; 55: 229-232.
    CrossrefPubMedGoogle Scholar
  • 4 Kawano N. et al. Portal vein thrombosis during eltrombopag treatment for immune thrombocytopenic purpura in a patient with liver cirrhosis due to hepatitis C viral infection. J Clin Exp Hematop 2013; 53: 151-155.
    CrossrefPubMedGoogle Scholar
  • 5 Terrault NA. et al. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure. J Hepatol 2014; 61: 1253-1259.
    CrossrefPubMedGoogle Scholar
  • 6 Afdhal NH. et al. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology 2014; 146: 442-452 e1.
    CrossrefPubMedGoogle Scholar
  • 7 Zocco MA. et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol 2009; 51: 682-689.
    CrossrefPubMedGoogle Scholar
  • 8 Saleh MN. et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013; 121: 537-545.
    CrossrefPubMedGoogle Scholar
  • 9 Qi X, Han G, Fan D. Management of portal vein thrombosis in liver cirrhosis. Nat Rev Gastroenterol Hepatol 2014; 11: 435-446.
    CrossrefPubMedGoogle Scholar
  • 10 Qi X. et al. Occlusive portal vein thrombosis as a new marker of decompensated cirrhosis. Med Hypotheses 2011; 76: 522-526.
    CrossrefPubMedGoogle Scholar
  • 11 Dentali F. et al. Inherited thrombophilic abnormalities and risk of portal vein thrombosis. a meta-analysis. Thromb Haemost 2008; 99: 675-682.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Qi X. et al. Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014; 12: 1801-1812 e7.
    CrossrefPubMedGoogle Scholar